Related Experiment Videos

More about: prognostic importance of low c-erbB2 expression in breast tumors

R Dittadi, M Gion

Journal of the National Cancer Institute

|September 7, 2000

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project.

ESMO open·2026

Comparing [18F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial.

ESMO open·2025

Redefining clinical trial strategic design to support drug approval in medical oncology.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

Results of a patient-level pooled analysis of three studies of trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastasis.

ESMO open·2025

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial.

ESMO open·2024

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.

BMC cancer·2022

See all related articles